Market Place
Sourcing Support
Replimune Announces Proposed Public Offering
25 Nov 2024 //
GLOBENEWSWIRE
Replimune Announces Pricing of Upsized Public Offering
25 Nov 2024 //
GLOBENEWSWIRE
Replimune Receives Breakthrough Therapy Designation for RP1
21 Nov 2024 //
GLOBENEWSWIRE
Replimune Reports Fiscal Q2 2025 Financial Results & Update
12 Nov 2024 //
GLOBENEWSWIRE
Replimune Presents RP1 + Nivolumab Data in Failed Melanoma
09 Nov 2024 //
GLOBENEWSWIRE
Replimune Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
08 Nov 2024 //
GLOBENEWSWIRE
Replimune to Present at SITC 39th Annual Meeting
30 Oct 2024 //
GLOBENEWSWIRE
Replimune Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
09 Oct 2024 //
GLOBENEWSWIRE
Replimune to Present at Two Upcoming Investor Conferences
01 Oct 2024 //
GLOBENEWSWIRE
Replimune Presents RP1 Data In Anti-PD1 Failed Melanoma At ESMO 2024
15 Sep 2024 //
GLOBENEWSWIRE
Replimune Confirms BLA Submission On Track For 2H 2024
09 Sep 2024 //
GLOBENEWSWIRE
Stockholders Elect Madhavan Balachandran To Board Of Directors
05 Sep 2024 //
GLOBENEWSWIRE
Replimune`s IGNYTE Trial Data Selected For ESMO 2024 Presentation
22 Aug 2024 //
GLOBENEWSWIRE
Replimune Doses First Patient In IGNYTE-3 Melanoma Trial
13 Aug 2024 //
GLOBENEWSWIRE
Replimune Reports Q1 2025 Results And Provides Corporate Update
08 Aug 2024 //
GLOBENEWSWIRE
Replimune to Present at Two Upcoming Investor Conferences
30 Jul 2024 //
GLOBENEWSWIRE
Replimune Announces $100 Million Private Placement Financing
13 Jun 2024 //
GLOBENEWSWIRE
Replimune To Present At Goldman Healthcare Conference
06 Jun 2024 //
GLOBENEWSWIRE
Replimune Announces Positive IGNYTE Data Of RP1 Plus Nivolumab In Melanoma
06 Jun 2024 //
GLOBENEWSWIRE
Replimune`s RP1, RP2 Data At 2024 ASCO Annual Meeting
03 Jun 2024 //
GLOBENEWSWIRE
Replimune Presentation Scheduled: 2024 Asco Annual Meeting Featured
23 May 2024 //
GLOBENEWSWIRE
Replimune Reports FY 2024 Financials, Corporate Update
16 May 2024 //
GLOBENEWSWIRE
Interim Results from the ARTACUS Trial will Presented at AACR
07 Apr 2024 //
GLOBENEWSWIRE
Replimune to Present at the American Association for Cancer Annual Meeting 2024
06 Mar 2024 //
GLOBENEWSWIRE
Replimune Reports Fiscal Third Quarter 2024 Financial Results
08 Feb 2024 //
GLOBENEWSWIRE
Replimune shares halve as skin cancer drug fails phase 2
05 Dec 2023 //
FIERCE BIOTECH
Replimune Reports Fiscal Second Quarter 2024 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Replimune Presents Interim Results from the ARTACUS Clinical Trial of RP1
03 Nov 2023 //
GLOBENEWSWIRE
Replimune Announces Appointment of Emily Hill as Chief Financial Officer
19 Sep 2023 //
GLOBENEWSWIRE
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19 Sep 2023 //
GLOBENEWSWIRE
Replimune Reports Fiscal First Quarter 2024 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
Replimune to Present at Two Upcoming Investor Conferences
01 Aug 2023 //
GLOBENEWSWIRE
Replimune and Incyte Enter into Collaboration to Evaluate RP1 and INCB99280
31 Jul 2023 //
BUSINESSWIRE
Replimune Announces Sander Slootweg will Depart from its Board of Directors
20 Jul 2023 //
FINANCE YAHOO
Replimune Presents Initial RP1 Data from the ARTACUS Clinical Trial at ATC
06 Jun 2023 //
GLOBENEWSWIRE
Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors
05 Jun 2023 //
GLOBENEWSWIRE
Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort Data
03 Jun 2023 //
GLOBENEWSWIRE
Replimune to Present at the Jefferies Global Healthcare Conference
01 Jun 2023 //
GLOBENEWSWIRE
Replimune to Present at the 2023 ASCO Annual Meeting
25 May 2023 //
GLOBENEWSWIRE
Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results
18 May 2023 //
GLOBENEWSWIRE
Replimune to Participate in the Piper Sandler Spring Biopharma Symposium
09 May 2023 //
GLOBENEWSWIRE
Replimune to Present at Two Upcoming Investor Conferences
08 Mar 2023 //
GLOBENEWSWIRE
Replimune Reports Fiscal Q3 Financial Results and Provides Corporate Update
09 Feb 2023 //
GLOBENEWSWIRE
Replimune to Present at the Virtual SVB Securities Global Biopharma Conference
07 Feb 2023 //
GLOBENEWSWIRE
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Jan 2023 //
PRESS RELEASE
Replimune Appoints Chris Sarchi, as CCO and Sushil Patel as CSO
04 Jan 2023 //
GLOBENEWSWIRE
Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference
03 Jan 2023 //
GLOBENEWSWIRE
Replimune looks to rope in $225M on the back of melanoma data
09 Dec 2022 //
ENDPTS
Replimune announces data from anti-PD1 failed melanoma cohort of IGNYTE trial
08 Dec 2022 //
PHARMABIZ
Replimune Announces Pricing of Public Offering
08 Dec 2022 //
GLOBENEWSWIRE
Replimune Announces Proposed Public Offering
07 Dec 2022 //
PRESS RELEASE
Replimune Enters into Clinical Collaboration Agreement with Roche
07 Dec 2022 //
GLOBENEWSWIRE
Replimune Announces +ve Initial Data from the Anti-PD1 Failed Melanoma Cohor
07 Dec 2022 //
GLOBENEWSWIRE
Replimune to Present at the Piper Sandler 34th Annual Healthcare Conference
23 Nov 2022 //
GLOBENEWSWIRE
Replimune to Host Virtual Investor Event on December 7, 2022
22 Nov 2022 //
GLOBENEWSWIRE
Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate
03 Nov 2022 //
GLOBENEWSWIRE
Oncolytic experts at Replimune reload with $200M loan as biotech collects data
07 Oct 2022 //
ENDPTS
Replimune Secures $200 Million in Non-Dilutive Debt Financing
07 Oct 2022 //
GLOBENEWSWIRE
Replimune’s HSV fights advanced cancers in Phase I trial
23 Sep 2022 //
CLINICALTRIALSARENA
Replimune to Present at Two Upcoming Investor Conferences
01 Aug 2022 //
GLOBENEWSWIRE
